Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Dry heat treatment stabilizer for human blood coagulation factor VIII and application thereof

A technology of human blood coagulation factor and dry heat treatment, applied in coagulation/fibrinolytic factors, enzyme stabilization, factor VII, etc., can solve the problems of low activity recovery rate of human blood coagulation factor VIII, low application value, low cost, etc., and achieve good clinical results Application prospects, low cost, and few types of effects

Active Publication Date: 2013-02-13
CHENGDU RONGSHENG PHARMA
View PDF2 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The stabilizer has only two components, does not need to use a large amount of human serum albumin, and is low in cost, but the activity recovery rate of human coagulation factor VIII is the lowest, and its practical application value is low

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dry heat treatment stabilizer for human blood coagulation factor VIII and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Embodiment 1 Preparation of human coagulation factor VIII preparation of the present invention

[0023] 1. Preparation method

[0024] Ⅰ. Separation and purification

[0025] (1) Using fresh frozen plasma as raw material, melt the plasma and centrifuge to prepare cryoprecipitate, dissolve the cryoprecipitate in 0.02M Tris buffer, precipitate with 30% polyethylene glycol, absorb with aluminum hydroxide and centrifuge to obtain the supernatant;

[0026] (2) After the supernatants were combined and clarified, Tween-80 and tributyl phosphate were added to make the final concentrations 1% and 0.3%, respectively, and treated at 25°C±1°C for 6 hours to complete the first virus inactivation (that is, SD virus inactivated);

[0027] (3) Use Toyopearl DEAE 650M as the gel for further purification by ion exchange chromatography, the buffer is 0.001M sodium citrate buffer, by changing the sodium chloride ionic strength of the chromatography buffer , and the eluate containing hum...

Embodiment 2

[0031] Embodiment 2 Preparation of human coagulation factor VIII preparation of the present invention

[0032] 1. Preparation method

[0033] Ⅰ. Separation and purification

[0034] (1) Using fresh frozen plasma as raw material, melt the plasma and centrifuge to prepare cryoprecipitate, dissolve the cryoprecipitate in 0.02M Tris buffer, precipitate with 30% polyethylene glycol, absorb with aluminum hydroxide and centrifuge to obtain the supernatant;

[0035] (2) After the supernatants were combined and clarified, Tween-80 and tributyl phosphate were added to make the final concentrations 1% and 0.3%, respectively, and treated at 25°C±1°C for 6 hours to complete the first virus inactivation (that is, SD virus inactivated);

[0036] (3) Using Toyopearl DEAE 650M as the gel as the filler for further purification by ion exchange chromatography, the buffer is 0.05M sodium citrate buffer, and collected by changing the sodium chloride ionic strength of the chromatography buffer El...

Embodiment 3

[0040] Embodiment 3 Preparation of human coagulation factor VIII preparation of the present invention

[0041] 1. Preparation method

[0042] Ⅰ. Separation and purification

[0043] (1) Using fresh frozen plasma as raw material, melt the plasma and centrifuge to prepare cryoprecipitate, dissolve the cryoprecipitate in 0.02M Tris buffer, precipitate with 30% polyethylene glycol, absorb with aluminum hydroxide and centrifuge to obtain the supernatant;

[0044] (2) After the supernatants were combined and clarified, Tween-80 and tributyl phosphate were added to make the final concentrations 1% and 0.3%, respectively, and treated at 25°C±1°C for 6 hours to complete the first virus inactivation (that is, SD virus inactivation);

[0045] (3) Use Toyopearl DEAE 650M as the gel as the filler for further purification by ion exchange chromatography, the buffer is 0.02M sodium citrate buffer, and the sodium chloride ionic strength of the chromatography buffer is changed to collect and ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a dry heat treatment stabilizer for human blood coagulation factor VIII, which comprises the following proportions of components: 0.005M-0.015M of sodium citrate, 0.001M-0.002M of calcium chloride, 0. 15M-0.25M of arginine hydrochloride, and 6-10g / L of human serum albumin. The invention also discloses a human blood coagulation factor VIII preparation and a preparation method of the human blood coagulation factor VIII preparation. The dry heat treatment stabilizer for human blood coagulation factor VIII provided by the invention can maintain the activity of the human blood coagulation factor VIII, and is low in cost, thus having good prospect in clinical application.

Description

technical field [0001] The invention relates to the field of plasma products, in particular to a dry heat treatment stabilizer for human blood coagulation factor VIII and its application. Background technique [0002] Human blood coagulation factor Ⅷ is a kind of coagulation factor, which is a composite factor consisting of two parts, of which the small molecular weight (about 260KD) part Ⅷ: C has procoagulant activity and acts as FIXa in the cascade reaction of blood coagulation A cofactor that activates FX into FXa, which can correct the coagulation abnormalities of hemophilia A. The preparation of human coagulation factor VIII from plasma is the main human coagulation factor VIII product currently on the market. Common methods for the preparation of human blood coagulation factor VIII include precipitation and chromatography. Precipitation includes isoelectric point precipitation, salting out precipitation, ether precipitation, acid precipitation and PEG precipitation. C...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K1/00A61K38/37
CPCC07K14/755C07K1/30C07K1/36A61K38/37A61K9/00C07K1/18C12N9/96
Inventor 牟蕾鲁涛王黔川李伟余伟
Owner CHENGDU RONGSHENG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com